NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE: ENZ), announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company’s proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health’s National Eye Institute (NEI). Robert Nussenblatt, MD, Chief of NEI’s Laboratory of Immunology, will serve as Principal Investigator.
